H1

MSL teams are realizing the power of using data insights to develop and execute successful #HCPengagement strategies. We spoke with Katie Shin, PharmD, Senior Global Director of Field Medical and Scientific Affairs at Sumitomo Pharma America, Inc. to hear her thoughts on how our partnership has helped her achieve their goals. During our conversation, Katie revealed how she and her team use H1 to maximize the KOL engagement efforts of her medical affairs team and to improve cross-functionality across Sumitomo’s business. Watch the full interview here: https://hubs.la/Q02X5JMZ0 You can learn more about HCP Universe here: https://hubs.la/Q02X5HQf0 #HCPs #KOLs #sumitomo #smpa #medicalaffairs #MSLs #HCPoutreach

#ICYMI We have expanded our #TrialLandscape platform to include diversity insights on 34 million patients being treated across England. With diversity insights on more than 500 million patients worldwide, this enhancement empowers sponsors to create diversity action plans that align with evolving standards in the U.S. and the U.K. In addition, we have introduced #SiteRescue—the industry’s first AI-powered tool designed to pinpoint healthcare providers, sites and investigators with the highest likelihood of success, tackling the challenges that often delay trials. Discover more about our upgraded Trial Landscape solution here 👉 https://hubs.la/Q02X0HLz0... #H1 #ClinicalTrials #HealthEquity #HealthcareDiversity #HealthcareInnovation #LifeSciences

In the past two years, more than 1 million people have been impacted by #LungCancer in the U.S. Lung cancer is one of the most commonly diagnosed cancers in both men and women, and is by far the leading cause of cancer death in the U.S. For this year’s Lung Cancer Awareness Month, we want to share some insights from the H1 database about research being done in this field. There are many studies being done to investigate new treatment options and many patients who could benefit from them. Learn more about how HCP Universe can provide an in-depth look into #oncology and other specialties of interest. https://hubs.la/Q02WYYhB0 #lungcancerawareness #lungcancerawarenessmonth

We're proud to share that we've been named a 2024 Fierce Healthcare Diversity, Equity, & Inclusion Awards finalist in the “Excellence in Data-Driven DEI Practices” category! This recognition underscores our dedication to pioneering systemic change by embedding #DEI at the heart of clinical trial design. Thank you to our incredible team and partners for championing this mission with us! See more here: https://hubs.la/Q02WYY_H0 #DEI #ClinicalTrials #FierceDEIAwards

In only a few days, H1's Co-founder and CEO, Ariel Katz will be joining a panel at the Galien Forum USA. Thank you to The Galien Foundation for organizing these sessions ahead of the Prix Galien USA awards ceremony. The panel, “BioPharma Pressure Points,” aims to better understand how structural and regulatory changes carry the potential to shift U.S. healthcare markets in new, unanticipated directions. Register at no cost here: https://lnkd.in/ehyx_hjr Use the code GALIENFORUM@VIPH1! Learn more about the event here: https://hubs.la/Q02WdMH50

Eli Lilly and Company is seeing improved patient safety after adjusting the ramp-up dosages of their Alzheimer’s therapy Kisunla. By more gradually introducing patients to the medication, Lilly has recorded lower incidences of brain swelling. The benefits have been seen to have the greatest effect in patients with a known genetic risk factor for Alzheimer’s disease. The reduction of risk for amyloid-related imaging abnormalities with edema (ARIA-E) was 41% overall, and 67% in patients with the genetic risk factor. Learn more: https://hubs.la/Q02WjP6N0 #alzheimersawarenessmonth #alzheimersawareness #alzheimers #alzheimersdisease

We’re heading to CNS Summit next week! Will you be there? Find out how we support pharma companies and CROs run successful and equitable clinical trials with well-rounded clinical intelligence. Visit us in booth 801 to learn more. And don’t miss our Regional VP of Sales, Ryan B., deliver an insightful presentation, “The Future of Clinical Trial Feasibility: How Health Equity Data is Shaping Tomorrow's Trials.” Hope to see you there! https://hubs.la/Q02Wk2GQ0 #CNSsummit #healthequity #clinicaltrialdiversity #sitefeasibility

One of the key topics that came up during our conversation with BioMarin Pharmaceutical Inc.’s Pamela Fearon was the current industry focus on FDA diversity action plans and how BioMarin is preparing for these new regulations. Improving patient representation is a major area of focus for BioMarin as an organization. Hear how they’ve been considering all angles for improving patient care, especially for underserved communities. Watch the full interview: #biomarin #fda #diversityactionplans #patientrepresentation #clinicaltrialdiversity #healthequity

Thanks again to everyone who came by to speak with us at #SCOPEEU this week! We really enjoyed hearing from you and answering your questions. If you’d like more information about how H1 supports clinical teams with site selection, identifying PIs, diversity planning and more, you can find helpful resources here: https://hubs.la/Q02WhTTG0 You can also request a demo of our Trial Landscape platform: https://hubs.la/Q02WhPwB0 #SCOPE #clinicaltrials #diversityinclusion #siteselection #sitefeasibility #diversityplanning

🚀🌍 Big news! We're proud to announce that we’ve expanded our #TrialLandscape platform to include diversity insights on 34 million patients being treated across England. With diversity insights on more than 500 million patients worldwide, this enhancement empowers sponsors to create diversity action plans that align with evolving #DEI standards in the U.S. and the U.K. In addition, we’re introducing #SiteRescue—the industry’s first AI-powered tool designed to pinpoint healthcare providers, sites and investigators with the highest likelihood of success, tackling the challenges that often delay trials. At H1, we’re committed to advancing global health equity - and it starts with making clinical trials more inclusive and successful. Discover more about our upgraded Trial Landscape solution here 👉 https://hubs.la/Q02WhDXG0